Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Claseprubart (DNTH103) in Multifocal Motor Neuropathy (MMN). The expected timing is based on the latest available company guidance and may change.
Ph2 MoMeNtum trial. Top-line results in H2 2026. 03/09/26:- MoMeNtum Ph2 trial ongoing; top-line results remain on track for 2H 2026. 05/05/26:- MoMeNtum Ph2 MMN trial ongoing; top-line results now guided to Q4 2026. 08/04/26:- MoMeNtum Ph2 enrollment completed with 46 patients. Topline expected December 2026.
Verification
Confirm timing and program details against the company announcement or filing.